Keyphrases
Hepatocellular Carcinoma
76%
Confidence Interval
62%
Tumor
58%
COVID-19
53%
Influenza Virus
50%
Overall Survival
39%
Virus
38%
Breast Cancer
38%
Inflammatory Bowel Disease
34%
United States
31%
In Cancer
31%
Multiple Myeloma
31%
Liver
30%
Prostate Cancer
27%
Clinical Trials
26%
Odds Ratio
25%
High Risk
25%
Lung Cancer
24%
Myelofibrosis
24%
Hazard Ratio
24%
New York City
23%
Chemotherapy
22%
T Cells
22%
Transcription Factor
21%
Gene Expression
20%
Liver Transplantation
20%
Graft-versus-host Disease (GvHD)
20%
Meta-analysis
19%
Interferon-α (IFN-α)
19%
Dendritic Cells
19%
Myeloproliferative Neoplasms
18%
Fibrosis
18%
Relapsed or Refractory multiple Myeloma
18%
Risk Factors
18%
Diabetes
17%
Lung Cancer Screening
17%
Obesity
17%
Hematopoietic Stem Cells
17%
Apoptosis
17%
Cancer Cells
17%
Breast Cancer Risk
17%
Colorectal Cancer
17%
Phase II Trial
17%
Hepatic Stellate Cells
16%
Bladder Cancer
16%
Inflammation
16%
Immune Response
15%
Non-small Cell Lung Cancer (NSCLC)
15%
Phosphorylation
15%
Older Adults
15%
Mount Sinai
15%
Lung
15%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
15%
Quality of Life
14%
Acute Myeloid Leukemia
14%
Progression-free Survival
14%
Clinical Outcomes
14%
Immune Checkpoint Inhibitors
14%
Mouse Model
14%
Type 2 Diabetes Mellitus (T2DM)
14%
Erythroid
14%
Cirrhosis
14%
Resection
13%
African American
13%
Liver Fibrosis
13%
Cancer Patients
13%
Tumor Cells
13%
Programmed Death-ligand 1 (PD-L1)
13%
Ulcerative Colitis
13%
Polycythemia Vera
13%
Tumor Microenvironment
13%
Phase II Study
13%
Hepatitis C Virus
13%
Crohn's Disease
13%
Drosophilidae
13%
Viral
12%
Signaling Pathway
12%
High-risk Human Papillomavirus (HR-HPV)
12%
Transplantation
12%
COVID-19 Pandemic
12%
Radiation Therapy
12%
Planar Cell Polarity
12%
Growth Factors
12%
Vaccination
11%
Metastasis
11%
Racial Disparities
11%
Adverse Events
11%
Innate Immune Response
11%
Hepatic Fibrosis
11%
CD8+ T Cells
11%
Malignancy
11%
MicroRNA
10%
Myelodysplastic Syndrome
10%
Magnetic Resonance Imaging
10%
Influenza-like Illness
10%
Radiotherapy
10%
Hepatic Stellate Cell Activation
10%
Overexpression
10%
Ruxolitinib
10%
Macrophages
10%
Medicine and Dentistry
Malignant Neoplasm
100%
Neoplasm
94%
Hepatocellular Carcinoma
71%
Disease
59%
Breast Cancer
55%
Lung Cancer
44%
COVID-19
40%
Overall Survival
39%
Prostate Cancer
36%
Multiple Myeloma
32%
Diseases
29%
Biological Marker
28%
Clinical Trial
28%
Magnetic Resonance Imaging
27%
Immunotherapy
23%
Severe Acute Respiratory Syndrome Coronavirus 2
23%
Infection
23%
Liver Transplantation
21%
Surgery
21%
Immunity
21%
Cancer
21%
Metastatic Carcinoma
21%
Chemotherapy
21%
Hazard Ratio
20%
Recurrent Disease
20%
Odds Ratio
20%
Fibrosis
20%
Transitional Cell Carcinoma
19%
Myelofibrosis
18%
Liver Fibrosis
17%
Lung
17%
Quality of Life
17%
Diabetes
16%
Systematic Review
16%
Human Immunodeficiency Virus
16%
Progression Free Survival
15%
Transplantation
15%
Cancer Risk
15%
Colorectal Carcinoma
15%
Cohort Analysis
15%
Radiation Therapy
15%
Bladder Cancer
15%
Adverse Event
15%
T Cell
15%
Cancer Therapy
14%
Inflammatory Bowel Disease
14%
Hepatic Stellate Cell
14%
Cancer Cell
14%
Oncology
14%
Meta-Analysis
14%
In Vitro
14%
Diagnosis
14%
Hematopoietic Cell
14%
Prevalence
14%
Liver Cirrhosis
13%
Cystectomy
13%
Health Care Cost
13%
Non Small Cell Lung Cancer
13%
Lung Cancer Screening
13%
Computer Assisted Tomography
13%
Adolescence
13%
Low Drug Dose
13%
Colonoscopy
12%
Clinician
12%
Myeloproliferative Neoplasm
12%
Wart Virus
12%
Melanoma
12%
Immune Checkpoint Inhibitor
12%
Biopsy Technique
12%
Liver Disease
11%
Nonalcoholic Fatty Liver
11%
Medicine
11%
Arm
11%
Receptor
10%
Comorbidity
10%
Crohn's Disease
10%
Inflammatory Bowel Disease
10%
Acute Myeloid Leukemia
10%
Gene Expression
10%
Maturity Onset Diabetes of the Young
10%
Cisplatin
10%
Ulcerative Colitis
10%
Logistic Regression Analysis
9%
Hepatitis C
9%
Urothelial Cancer
9%
Ovarian Cancer
9%
Myelodysplastic Syndrome
9%
Cholangiocarcinoma
9%
Body Mass Index
9%
Tumor Progression
9%
Immune Response
9%
Fibrogenesis
9%
Symptomatic Treatment
9%
Tumor Microenvironment
9%
Health Care
9%
Proportional Hazards Model
9%
Primary Health Care
8%
Tumor Cell
8%
Drug Therapy
8%
Polycythemia vera
8%